MCID: UTR037
MIFTS: 38

Uterine Corpus Sarcoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Uterine Corpus Sarcoma

MalaCards integrated aliases for Uterine Corpus Sarcoma:

Name: Uterine Corpus Sarcoma 11 14 71
Sarcoma of the Corpus Uteri 58
Sarcoma of Corpus Uteri 11
Sarcoma, Nos of Uterus 33
Sarcoma of Uterus 11
Uterine Sarcoma 33

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 11 DOID:5165
NCIt 49 C6339
SNOMED-CT 68 254877001
ICD10 via Orphanet 32 C54.2
UMLS via Orphanet 72 C0338113
Orphanet 58 ORPHA213620
ICD11 33 1319990901
UMLS 71 C0338113

Summaries for Uterine Corpus Sarcoma

Disease Ontology: 11 An uterine corpus cancer that is located in the muscles of the uterus or located in other tissues that support the uterus.

MalaCards based summary: Uterine Corpus Sarcoma, also known as sarcoma of the corpus uteri, is related to bizarre leiomyoma and sarcomatosis. An important gene associated with Uterine Corpus Sarcoma is NTRK1 (Neurotrophic Receptor Tyrosine Kinase 1), and among its related pathways/superpathways is Hippo-Merlin signaling dysregulation. The drugs Cisplatin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include muscles of the uterus, other tissues and uterus, and related phenotypes are Decreased substrate adherent cell growth and muscle

Related Diseases for Uterine Corpus Sarcoma

Diseases related to Uterine Corpus Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 bizarre leiomyoma 30.2 KIT CALD1
2 sarcomatosis 30.1 KIT CALD1
3 endometrial stromal sarcoma 30.1 KIT CALD1
4 mesenchymal cell neoplasm 30.0 NTRK1 KIT CALD1
5 myoma 29.8 KIT CALD1
6 hemangiopericytoma, malignant 29.8 KIT CALD1
7 mixed cell type cancer 29.8 KIT CALD1
8 spindle cell sarcoma 29.7 KIT CALD1
9 adenosarcoma 29.7 KIT CALD1
10 epithelioid leiomyosarcoma 29.6 KIT CALD1
11 retroperitoneal sarcoma 29.6 KIT CALD1
12 dermatofibrosarcoma protuberans 29.5 KIT CALD1
13 gastrointestinal stromal tumor 29.3 NTRK1 KIT CALD1
14 uterine sarcoma 11.3
15 uterine corpus endometrial stromal sarcoma 11.2
16 uterus leiomyosarcoma 11.2
17 uterine carcinosarcoma 11.2
18 leiomyosarcoma 10.9
19 leiomyoma 10.7
20 uterine inversion 10.3
21 endometrial cancer 10.3
22 sarcoma 10.2
23 factor vii deficiency 10.2
24 rhabdomyosarcoma 10.2
25 soft tissue sarcoma 10.2
26 rare tumor 10.2
27 endometrial adenocarcinoma 10.1
28 arthrogryposis, renal dysfunction, and cholestasis 1 10.1
29 small cell carcinoma 10.1
30 fibrosarcoma 10.1
31 vaginal discharge 10.1
32 carcinosarcoma 10.1
33 malignant gastric teratoma 10.1 NTRK1 KIT
34 small intestinal sarcoma 10.1 NTRK1 KIT
35 tenosynovial giant cell tumor 10.0 NTRK1 KIT
36 short stature, onychodysplasia, facial dysmorphism, and hypotrichosis 10.0
37 neutropenia 10.0
38 adenocarcinoma 10.0
39 ovarian small cell carcinoma 10.0
40 congenital mesoblastic nephroma 10.0 NTRK1 KIT
41 thymic carcinoma 10.0 NTRK1 KIT
42 urethra leiomyoma 10.0 KIT CALD1
43 ureter leiomyoma 10.0 KIT CALD1
44 esophagus sarcoma 10.0 KIT CALD1
45 infantile myofibromatosis 10.0 NTRK1 CALD1
46 glomangioma 10.0 KIT CALD1
47 glomangiomatosis 10.0 KIT CALD1
48 vagina leiomyosarcoma 10.0 KIT CALD1
49 bladder leiomyoma 10.0 KIT CALD1
50 gallbladder leiomyosarcoma 10.0 KIT CALD1

Graphical network of the top 20 diseases related to Uterine Corpus Sarcoma:



Diseases related to Uterine Corpus Sarcoma

Symptoms & Phenotypes for Uterine Corpus Sarcoma

GenomeRNAi Phenotypes related to Uterine Corpus Sarcoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 8.92 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 8.92 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 8.92 KIT NTRK1

MGI Mouse Phenotypes related to Uterine Corpus Sarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 8.92 CALD1 KIT NTRK1 SEC61A1

Drugs & Therapeutics for Uterine Corpus Sarcoma

Drugs for Uterine Corpus Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
2
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
3
Ifosfamide Approved Phase 3 3778-73-2 3690
4
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
5
Lenograstim Approved, Investigational Phase 3 135968-09-1
6
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
7
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
8
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
9
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
10
Palifosfamide Investigational Phase 3 31645-39-3 100427
11 Alkylating Agents Phase 3
12 Antineoplastic Agents, Alkylating Phase 3
13 Anti-Bacterial Agents Phase 3
14 Anti-Infective Agents Phase 3
15 Angiogenesis Inhibitors Phase 3
16 Immunosuppressive Agents Phase 3
17 Immunologic Factors Phase 3
18 Antiviral Agents Phase 3
19 Antimitotic Agents Phase 3
20 Adjuvants, Immunologic Phase 3
21 Antimetabolites Phase 3
22 Tubulin Modulators Phase 3
23 Immunoglobulins, Intravenous Phase 3
24 Immunoglobulins Phase 3
25 Immunoglobulin G Phase 3
26 Antibodies, Monoclonal Phase 3
27 Antibodies Phase 3
28 Antineoplastic Agents, Immunological Phase 3
29 Endothelial Growth Factors Phase 3
30 Mitogens Phase 3
31 Antibiotics, Antitubercular Phase 3
32 Liposomal doxorubicin Phase 3
33
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
34
Aflibercept Approved Phase 2 862111-32-8 124490314
35
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
36
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 11128-99-7, 4474-91-3 172198
37
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
38
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
39
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
40
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
41
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
42
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
43
Saracatinib Investigational Phase 2 379231-04-6 10302451
44 Epothilones Phase 2
45 Epothilone B Phase 2 4456137
46 R04929097 Phase 1, Phase 2
47 Protein Kinase Inhibitors Phase 2
48
Angiotensinogen Phase 2 16133225
49 Antihypertensive Agents Phase 2
50 Angiotensin I (1-7) Phase 2

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
2 A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III Completed NCT00002706 Phase 3
3 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
4 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Active, not recruiting NCT03422198 Phase 3
5 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
6 A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
7 A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma Terminated NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
8 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00025220 Phase 2 Thalidomide
9 A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
10 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
11 A Phase II Evaluation of Docetaxel and Gemcitabine Plus G-CSF in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
12 A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
13 A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
14 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01220609 Phase 2 Ixabepilone
15 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01168232 Phase 2 Ixabepilone
16 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
17 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
18 A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas Completed NCT00390234 Phase 2 ziv-aflibercept
19 A Prospective Evaluation of a Palliative Radio-Surgical Approach for the Treatment of Gynecologic Malignancies Completed NCT01079832 Phase 2
20 A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma Completed NCT00238121 Phase 2 sorafenib tosylate
21 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
22 A Phase II Clinical Trial of Angiotensin 1-7 For the Second or Third Line Treatment of Patients With Metastatic or Unresectable Sarcomas Completed NCT01553539 Phase 2 therapeutic angiotensin-(1-7)
23 Psychosexual Intervention for Gynecologic and Breast Cancer Patients Completed NCT01764802 Phase 2
24 A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
25 A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00075400 Phase 2 imatinib mesylate
26 Phase II Randomized Trial to Evaluate Two Strategies: Continuing Versus Intermittent (Drug-holiday) Trabectedin-regimen in Patients With Advanced Soft Tissue Sarcoma Experiencing Response or Stable Disease After the Sixth Cycle Completed NCT01303094 Phase 2 Trabectedin
27 A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Uterine Sarcoma (HGUtS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment Active, not recruiting NCT01979393 Phase 2 Cabozantinib;Placebo
28 A Pilot Study of Peroral Vorinostat (SAHA) in Patients With Refractory Histone Deacetylase-positive Uterine Sarcoma Terminated NCT03509207 Phase 2 Vorinostat Oral Capsule
29 Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
30 A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors With an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumor Completed NCT01548482 Phase 1 Temsirolimus
31 Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors. Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
32 A Phase I Trial of Weekly 17-Allylamino-17 Demethoxygeldanamycin Completed NCT00004241 Phase 1 tanespimycin
33 Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen Completed NCT00020267 Phase 1 interleukin-2;MAGE-12 peptide vaccine;Montanide ISA-51
34 A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
35 Patient, Physician And Nurse Factors Associated With Entry Onto Clinical Trials And Completion Of Treatment For Women With Primary Or Recurrent Invasive Cancer Of The Uterine Corpus Or Uterine Cervix, All Stages Completed NCT01098630
36 A Randomized Trial of a Family Caregiver Palliative Care Intervention Completed NCT01846520
37 Randomized-Controlled, Pilot Study of the Effects of a Brief, Scripted Sexual Health Intervention on Sexual Function for Women With Gynecologic Cancer Completed NCT02096783
38 A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence Completed NCT01764789
39 A Pilot Randomized Control Trial to Evaluate Pelvic Floor Muscle Training for Urinary Incontinence Among Gynecologic Cancer Survivors Completed NCT01806350
40 Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors Recruiting NCT04634617
41 Surgical and Reproductive Results of Fertility-sparing Treatment for Low-grade Endometrial Stromal Sarcoma: A Retrospective Cohort Study Recruiting NCT05310318
42 Real-Time Identification of Lesions and Nerves by Using Indocyanine Green Fluorescent Imaging in Gynecological Surgery Recruiting NCT04224467
43 Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020) Available NCT03493165 Everolimus
44 Diagnostic Performances of Preoperative Echo-guided Uterine Biopsy in the Management of Suspect Uterine Sarcoma Tumors Not yet recruiting NCT04250766
45 A Pilot Safety and Toxicity Trial of Adjuvant Chemotherapy With Gemcitabine and Docetaxel and Radiation Therapy for Completely Resected Uterine Leiomyosarcoma Terminated NCT01958580 Gemcitabine Hydrochloride;Docetaxel
46 A Pilot Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Carcinosarcoma Terminated NCT01367301 paclitaxel;carboplatin
47 Distribution Of The Photosensitizer Motexafin Lutetium And Hypoxia In Patients With Malignancies Terminated NCT00087191 EF5;motexafin lutetium
48 Web-Based Coping and Communication Skills Intervention for Women Who Are Newly Diagnosed With Gynecological Cancer: A Pilot Study Withdrawn NCT03902379

Search NIH Clinical Center for Uterine Corpus Sarcoma

Genetic Tests for Uterine Corpus Sarcoma

Anatomical Context for Uterine Corpus Sarcoma

Organs/tissues related to Uterine Corpus Sarcoma:

FMA: Muscles Of The Uterus, Other Tissues
MalaCards : Uterus, Cervix, Breast, Ovary, Endothelial, Smooth Muscle, Lymph Node

Publications for Uterine Corpus Sarcoma

Articles related to Uterine Corpus Sarcoma:

(show top 50) (show all 1113)
# Title Authors PMID Year
1
Clinical manifestations and prognosis of unexpected uterine sarcoma of uterine fibroids in Tianjin China. 62
36474216 2022
2
A nomogram-based overall survival stratification to identify uterine sarcoma patients without distant metastases who may benefit from adjuvant radiotherapy. 62
36469973 2022
3
Uterine Sarcoma With FGFR1-TACC1 Gene Fusion: A Case Report and Review of the Literature. 62
36302190 2022
4
Development of a deep learning method for improving diagnostic accuracy for uterine sarcoma cases. 62
36385486 2022
5
Embryonal Rhabdomyosarcoma of the Uterine Cervix: A Clinicopathologic Study of 94 Cases Emphasizing Issues in Differential Diagnosis Staging, and Prognostic Factors. 62
35941719 2022
6
Expanding the spectrum of GLI1-altered mesenchymal tumors-A high-grade uterine sarcoma harboring a novel PAMR1::GLI1 fusion and literature review of GLI1-altered mesenchymal neoplasms of the gynecologic tract. 62
36222065 2022
7
Impact on prognosis of unexpected uterine sarcoma with scalpel morcellation or enucleation. 62
36164469 2022
8
Clinical characteristics and prognosis analysis of uterine sarcoma: a single-institution retrospective study. 62
36207687 2022
9
Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group. 62
36114030 2022
10
Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma. 62
35727598 2022
11
Description of a Novel ERBB4 -rearranged Uterine Sarcoma. 62
34570017 2022
12
BCOR Internal Tandem Duplication Associated Uterine Sarcoma: Expanding the Clinicopathologic Spectrum. 62
34456278 2022
13
Recurrent KAT6B/A::KANSL1 Fusions Characterize a Potentially Aggressive Uterine Sarcoma Morphologically Overlapping With Low-grade Endometrial Stromal Sarcoma. 62
35575789 2022
14
Xanthogranulomatous inflammation caused by K. pneumonia and nocardiosis mimicking a uterine tumor and invading the ureter and colon: A case report and review of the literature. 62
36088063 2022
15
Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines. 62
35640378 2022
16
Fertility-Sparing Management May Be Considered in Young Women with Uterine Sarcoma. 62
36012998 2022
17
Uterine Sarcoma: Retrospective Study From A Single institute. 62
35928081 2022
18
Is Adnexectomy Mandatory at the Time of Hysterectomy for Uterine Sarcomas? A Systematic Review and Meta-Analysis. 62
36143817 2022
19
Spindle Cell Sarcoma of the Uterine Corpus With Adipose Metaplasia: Expanding the Morphologic Spectrum of Neoplasms With MEIS1-NCOA2 Gene Fusion. 62
34166279 2022
20
Safety and feasibility of laterally extended endopelvic resection for sarcoma in the female genital tract: a prospective cohort study. 62
35754364 2022
21
Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis. 62
35780401 2022
22
Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements. 62
35149769 2022
23
Development and validation of tumor-size-stratified prognostic nomograms for patients with uterine sarcoma: A SEER database analysis. 62
35841316 2022
24
Different effects of magnetic field on drug activity in human uterine sarcoma cell lines MES-SA and MES-SA/Dx5. 62
35793396 2022
25
Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2019 and annual treatment report for 2014. 62
35633031 2022
26
The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma. 62
35883603 2022
27
Advances in the Preoperative Identification of Uterine Sarcoma. 62
35884577 2022
28
Adjuvant radiotherapy shows benefit in selected stage I uterine sarcoma: A risk scoring system based on a population analysis. 62
35277934 2022
29
"Uterine Sarcoma Auto-Amputation in an Infant with DICER1 Syndrome". 62
34973456 2022
30
The value of SOX2 in the differential diagnosis of SMARCA4 (BRG1)-deficient uterine neoplasms. 62
35331811 2022
31
Cellular context determines DNA methylation profiles in SWI/SNF-deficient cancers of the gynecologic tract. 62
35218556 2022
32
FDG PET/MRI in Synchronous Uterine Adenocarcinoma and Leiomyosarcoma. 62
35353760 2022
33
Discrepancies in pathological diagnosis of endometrial stromal sarcoma: a multi-institutional retrospective study from the Japanese clinical oncology group. 62
35339567 2022
34
Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report. 62
35586703 2022
35
Effect of tumor morcellation in patients with early uterine sarcoma: a multicenter study in Germany 62
35263843 2022
36
Endometrial stromal tumors: Diagnostic updates and challenges. 62
35067405 2022
37
Uterine Sarcoma Presenting as Hypercapnic Respiratory Failure. 62
35813696 2022
38
A novel nomogram for predicting cancer-specific survival in women with uterine sarcoma: a large population-based study. 62
35568940 2022
39
Effect of Tumor Targeted-Anthracycline Nanomedicine, HPMA Copolymer-Conjugated Pirarubicin (P-THP) against Gynecological Malignancies. 62
35629236 2022
40
[Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors]. 62
35658326 2022
41
A Case of COL1A1-PDGFB Fusion Uterine Sarcoma. 62
35551153 2022
42
SMARCA4-deficient Undifferentiated Uterine Sarcoma: Clinicopathological Features of an Emerging Entity. 62
35466749 2022
43
Spindle Cell Sarcoma of the Uterus Harboring MEIS1::NCOA1 Fusion Gene and Mimicking Endometrial Stromal Sarcoma. 62
35477326 2022
44
'I thought I had fibroids, and now I don't': a mixed method study on health-related quality of life in uterine sarcoma patients. 62
35443673 2022
45
[Resection of an "inoperable" uterine sarcoma through the cooperation of plastic surgery and gynecology in a massively obese patient]. 62
35158398 2022
46
Novel Therapeutics in the Treatment of Uterine Sarcoma. 62
35714303 2022
47
Amphiphilic Cell-Penetrating Peptides Containing Natural and Unnatural Amino Acids as Drug Delivery Agents. 62
35406720 2022
48
Preoperative clinical characteristics between uterine sarcoma and leiomyoma in patients with uterine mass, a case-control study. 62
35074691 2022
49
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2018 and Annual Treatment Report for 2013. 62
35026864 2022
50
Characteristic of Uterine Rhabdomyosarcoma by Algorithm of Potential Biomarkers for Uterine Mesenchymal Tumor. 62
35448164 2022

Variations for Uterine Corpus Sarcoma

Expression for Uterine Corpus Sarcoma

Search GEO for disease gene expression data for Uterine Corpus Sarcoma.

Pathways for Uterine Corpus Sarcoma

Pathways related to Uterine Corpus Sarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.58 NTRK1 KIT

GO Terms for Uterine Corpus Sarcoma

Biological processes related to Uterine Corpus Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to radiation GO:0009314 8.8 NTRK1 KIT

Molecular functions related to Uterine Corpus Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 NTRK1 KIT

Sources for Uterine Corpus Sarcoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....